Intra-Cellular Therapies Inc. (NASDAQ:ITCI) shares saw strong trading volume on Monday . 366,238 shares changed hands during trading, an increase of 23% from the previous session’s volume of 298,531 shares.The stock last traded at $40.63 and had previously closed at $40.80.

A number of research analysts have weighed in on the stock. Cowen and Company reissued a “buy” rating on shares of Intra-Cellular Therapies in a research report on Wednesday, June 29th. Leerink Swann reissued a “buy” rating on shares of Intra-Cellular Therapies in a research report on Saturday, April 30th. Zacks Investment Research raised shares of Intra-Cellular Therapies from a “sell” rating to a “hold” rating in a research report on Tuesday, May 17th. Finally, Piper Jaffray Cos. reaffirmed an “overweight” rating and set a $57.00 price objective on shares of Intra-Cellular Therapies in a research report on Wednesday, June 22nd. One analyst has rated the stock with a sell rating, one has assigned a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus price target of $70.78.

The stock has a 50-day moving average of $39.18 and a 200-day moving average of $34.74. The firm’s market capitalization is $1.78 billion.

Other hedge funds and institutional investors have added to or reduced their stakes in the company. BlackRock Advisors LLC increased its position in Intra-Cellular Therapies by 1.7% in the fourth quarter. BlackRock Advisors LLC now owns 1,199,043 shares of the biopharmaceutical company’s stock worth $64,497,000 after buying an additional 19,938 shares during the period. Jennison Associates LLC increased its position in Intra-Cellular Therapies by 212.9% in the fourth quarter. Jennison Associates LLC now owns 1,257,846 shares of the biopharmaceutical company’s stock worth $67,660,000 after buying an additional 855,846 shares during the period. Marshall Wace LLP increased its position in Intra-Cellular Therapies by 23.5% in the fourth quarter. Marshall Wace LLP now owns 23,148 shares of the biopharmaceutical company’s stock worth $1,245,000 after buying an additional 4,410 shares during the period. New York State Common Retirement Fund increased its position in Intra-Cellular Therapies by 27.9% in the fourth quarter. New York State Common Retirement Fund now owns 26,600 shares of the biopharmaceutical company’s stock worth $1,431,000 after buying an additional 5,800 shares during the period. Finally, California Public Employees Retirement System increased its position in Intra-Cellular Therapies by 505.4% in the fourth quarter. California Public Employees Retirement System now owns 78,700 shares of the biopharmaceutical company’s stock worth $4,233,000 after buying an additional 65,700 shares during the period.

Intra-Cellular Therapies, Inc (ITI) is a biopharmaceutical company. The Company is focused on the discovery and clinical development of small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system (CNS).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.